Plasma Brain Natriuretic Peptide-Guided Therapy to Improve Outcome in Heart Failure. The STARS-BNP Multicenter Study

Journal of the American College of Cardiology

Volumn 49, Issue 16, 2007, Pages 1733-1739

  Jourdain, Patrick ^a,b,e   Jondeau, Guillaume ^c   Funck, François ^e   Gueffet, Pascal ^f   Le Helloco, Alain ^g   Donal, Erwan ^g   Aupetit, Jean F ^h   Aumont, Marie C ^c   Galinier, Michel ⁱ   Eicher, Jean C ^j   Cohen Solal, Alain ^d   Juillière, Yves ^k  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c BICHAT HOSPITAL   (France)

^d Section of Radiology   (France)

^e Hospitalier René Dubos   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h Hôpital Saint Luc Saint Joseph   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j DIJON UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; SPIRONOLACTONE; VALSARTAN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEART FAILURE; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PEPTIDE ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RELEVANCE VECTOR MACHINE; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; CARDIAC OUTPUT, LOW; DIURETICS; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 34247135389     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.10.081     Document Type: Article

References (32)

1. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure. ESC guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560
2. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 104 (2001) 2996-3007
3. Cleland J.G.F., Swedberg K., Follath F., et al. The EuroHeart Failure survey program-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24 (2003) 442-463
4. McCullough P.A., Philbin E.F., Spertus J.A., et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39 (2002) 60-69
5. Redfield M.M. Heart failure, an epidemic of uncertain proportions. N Engl J Med 347 (2002) 1442-1444
6. Nakao K., Ogawa Y., Suga S.I., et al. Molecular biology and biochemistry of the natriuretic peptide system. J Hypertension 10 (1992) 907-912
7. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195-203
8. Hosoda K., Nakao K., Mukoyama M., et al. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension 17 (1991) 1152-1156
9. Levin E.R., Gardner D.G., and Samson W. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
10. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
11. McCullough P.A., Nowak R.M., McCord J., et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) multinational study. Circulation 106 (2002) 416-422
12. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 436-442
13. Koglin J., Pehlivanli S., Schwaiblmair M., et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
14. Bettencourt P., Ferreira A., Dias P., et al. Predictors of prognosis in mild to moderate heart failure. J Card Fail 6 (2000) 306-313
15. Gardner R.S., Ozalo F., Murday A.J., Robb S.D., and McDonagh T.A. N terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24 (2003) 1735-1743
16. Yoshimura M., Mizuno Y., Nakayama M., et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 112 (2002) 716-720
17. Ferreira A., Bettencourt P., Dias P., et al. Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clin Sci (Lond) 1 (2001) 100-105
18. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 (1999) 1126-1132
19. Latini R., Mason S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (2002) 2454-2458
20. Tsutamoto T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide in patients with congestive heart failure. J Am Coll Cardiol 37 (2001) 1228-1233
21. Bettencourt P., Frioes F., Azevedo A., et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 93 (2004) 45-48
22. Richards A.M., Doughty R., Nicholls M.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37 (2001) 1781-1787
23. Richards A., Doughty R., and Nicholls M. Neurohumoral prediction of benefit from carvedilol in ischaemic left ventricular dysfunction. Circulation 99 (1999) 786-792
24. Fung J.W., Yu C.M., Yip G., et al. Effect of beta-blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92 (2003) 406-410
25. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
26. Troughton R.W., Frampton C.M., and Yandle T.G. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
27. Richards M., and Throughton R.W. NT pro-BNP in heart failure therapy decision and monitoring. Eur J Heart Failure 6 (2004) 351-354
28. Vogeser M., and Jacob K. B-type natriuretic peptide (BNP)-validation of an immediate response assay. Clin Lab 47 (2001) 29-33
29. The Study Group of Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey program-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24 (2003) 464-474
30. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
31. Poole-Wilson P.A., Swedberg K., Cleland J.G.F., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
32. Maeda K., Tsutamoto T., and Wada A. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 (1998) 825-832